311 related articles for article (PubMed ID: 19577811)
1. Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
Tegla CA; Cudrici C; Rus V; Ito T; Vlaicu S; Singh A; Rus H
J Neuroimmunol; 2009 Aug; 213(1-2):3-11. PubMed ID: 19577811
[TBL] [Abstract][Full Text] [Related]
2. Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
Rus H; Cudrici C; Niculescu F; Shin ML
J Neuroimmunol; 2006 Nov; 180(1-2):9-16. PubMed ID: 16905199
[TBL] [Abstract][Full Text] [Related]
3. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection.
Rus H; Cudrici C; Niculescu F
Ann Med; 2005; 37(2):97-104. PubMed ID: 16026117
[TBL] [Abstract][Full Text] [Related]
4. Oligodendrocyte cell death in pathogenesis of multiple sclerosis: Protection of oligodendrocytes from apoptosis by complement.
Cudrici C; Niculescu T; Niculescu F; Shin ML; Rus H
J Rehabil Res Dev; 2006; 43(1):123-32. PubMed ID: 16847778
[TBL] [Abstract][Full Text] [Related]
5. Effects of complement C5 on apoptosis in experimental autoimmune encephalomyelitis.
Niculescu T; Weerth S; Niculescu F; Cudrici C; Rus V; Raine CS; Shin ML; Rus H
J Immunol; 2004 May; 172(9):5702-6. PubMed ID: 15100315
[TBL] [Abstract][Full Text] [Related]
6. The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS.
Reynolds R; Dawson M; Papadopoulos D; Polito A; Di Bello IC; Pham-Dinh D; Levine J
J Neurocytol; 2002; 31(6-7):523-36. PubMed ID: 14501221
[TBL] [Abstract][Full Text] [Related]
7. Interferon regulatory factor 1 regulation of oligodendrocyte injury and inflammatory demyelination.
Loda E; Balabanov R
Rev Neurosci; 2012 Jan; 23(2):145-52. PubMed ID: 22499673
[TBL] [Abstract][Full Text] [Related]
8. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
[TBL] [Abstract][Full Text] [Related]
9. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
Mc Guire C; Volckaert T; Wolke U; Sze M; de Rycke R; Waisman A; Prinz M; Beyaert R; Pasparakis M; van Loo G
J Immunol; 2010 Dec; 185(12):7646-53. PubMed ID: 21068410
[TBL] [Abstract][Full Text] [Related]
10. FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models.
Rajendran R; Böttiger G; Stadelmann C; Karnati S; Berghoff M
Cells; 2021 Apr; 10(4):. PubMed ID: 33924474
[TBL] [Abstract][Full Text] [Related]
11. Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.
Khalaj AJ; Hasselmann J; Augello C; Moore S; Tiwari-Woodruff SK
J Steroid Biochem Mol Biol; 2016 Jun; 160():43-52. PubMed ID: 26776441
[TBL] [Abstract][Full Text] [Related]
12. Oligodendrocyte-Specific Deletion of
Rajendran R; Rajendran V; Giraldo-Velasquez M; Megalofonou FF; Gurski F; Stadelmann C; Karnati S; Berghoff M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502405
[TBL] [Abstract][Full Text] [Related]
13. C5b-9 complement complex in autoimmune demyelination: dual role in neuroinflammation and neuroprotection.
Rus H; Cudrici C; Niculescu F
Adv Exp Med Biol; 2006; 586():139-51. PubMed ID: 16893070
[No Abstract] [Full Text] [Related]
14. The role of iron in the pathogenesis of experimental allergic encephalomyelitis and multiple sclerosis.
LeVine SM; Chakrabarty A
Ann N Y Acad Sci; 2004 Mar; 1012():252-66. PubMed ID: 15105271
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination.
Stoffels JM; de Jonge JC; Stancic M; Nomden A; van Strien ME; Ma D; Sisková Z; Maier O; Ffrench-Constant C; Franklin RJ; Hoekstra D; Zhao C; Baron W
Brain; 2013 Jan; 136(Pt 1):116-31. PubMed ID: 23365094
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CXCR2 signaling promotes recovery in models of multiple sclerosis.
Kerstetter AE; Padovani-Claudio DA; Bai L; Miller RH
Exp Neurol; 2009 Nov; 220(1):44-56. PubMed ID: 19616545
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
[TBL] [Abstract][Full Text] [Related]
18. Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.
Prinz J; Karacivi A; Stormanns ER; Recks MS; Kuerten S
PLoS One; 2015; 10(12):e0144847. PubMed ID: 26658811
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis.
Dhib-Jalbut S
Neurology; 2007 May; 68(22 Suppl 3):S13-21; discussion S43-54. PubMed ID: 17548563
[TBL] [Abstract][Full Text] [Related]
20. Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.
Liu Y; Given KS; Harlow DE; Matschulat AM; Macklin WB; Bennett JL; Owens GP
Acta Neuropathol Commun; 2017 Mar; 5(1):25. PubMed ID: 28340598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
